Literature DB >> 4093855

[Studies on Ganoderma lucidum. I. Efficacy against hypertension and side effects].

K Kanmatsuse, N Kajiwara, K Hayashi, S Shimogaichi, I Fukinbara, H Ishikawa, T Tamura.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4093855     DOI： 10.1248/yakushi1947.105.10_942

Source DB:  PubMed          Journal:  Yakugaku Zasshi        ISSN： 0031-6903            Impact factor:   0.302


× No keyword cloud information.
  6 in total

1.  Antimicrobial activity of Ganoderma lucidum extract alone and in combination with some antibiotics.

Authors:  S Y Yoon; S K Eo; Y S Kim; C K Lee; S S Han
Journal:  Arch Pharm Res       Date:  1994-12       Impact factor: 4.946

Review 2.  Accessing biological actions of Ganoderma secondary metabolites by in silico profiling.

Authors:  Ulrike Grienke; Teresa Kaserer; Florian Pfluger; Christina E Mair; Thierry Langer; Daniela Schuster; Judith M Rollinger
Journal:  Phytochemistry       Date:  2014-11-06       Impact factor: 4.072

Review 3.  Ganoderma lucidum mushroom for the treatment of cardiovascular risk factors.

Authors:  Nerida L Klupp; Dennis Chang; Fiona Hawke; Hosen Kiat; Huijuan Cao; Suzanne J Grant; Alan Bensoussan
Journal:  Cochrane Database Syst Rev       Date:  2015-02-17

Review 4.  The beneficial effects of Ganoderma lucidum on cardiovascular and metabolic disease risk.

Authors:  Sze Wa Chan; Brian Tomlinson; Paul Chan; Christopher Wai Kei Lam
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

5.  Anti-inflammatory activities of Ganoderma lucidum (Lingzhi) and San-Miao-San supplements in MRL/lpr mice for the treatment of systemic lupus erythematosus.

Authors:  Zhe Cai; Chun Kwok Wong; Jie Dong; Delong Jiao; Man Chu; Ping Chung Leung; Clara Bik San Lau; Ching Po Lau; Lai Shan Tam; Christopher Wai Kei Lam
Journal:  Chin Med       Date:  2016-04-29       Impact factor: 5.455

6.  A double-blind, randomised, placebo-controlled trial of Ganoderma lucidum for the treatment of cardiovascular risk factors of metabolic syndrome.

Authors:  Nerida L Klupp; Hosen Kiat; Alan Bensoussan; Genevieve Z Steiner; Dennis H Chang
Journal:  Sci Rep       Date:  2016-08-11       Impact factor: 4.379
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.